Keyphrases
Israel
100%
Human Immunodeficiency Virus Type 1 (HIV-1)
32%
Israeli
23%
HIV Patients
22%
Odds Ratio
21%
Risk Factors
18%
COVID-19
18%
Methicillin-resistant Staphylococcus Aureus
18%
Hospitalized Patients
16%
West Nile Fever
15%
Bacteremia
14%
Confidence Interval
14%
Virus
12%
Invasive Pneumococcal Disease
12%
Quinolones
11%
Antibiotic Use
10%
13-valent Pneumococcal Conjugate Vaccine (PCV13)
10%
Hospital Admission
9%
Nationwide Surveillance
9%
Surgical Site Infection
9%
Clinical Characteristics
9%
Viral Load
9%
Risk Behavior
9%
Antibiotics
8%
Escherichia Coli
7%
Hospitalization
7%
Infected Patients
7%
Ethiopian
7%
HIV-1 Subtype C
7%
HIV-positive
7%
Randomized Controlled Trial
7%
Empirical Therapy
7%
Encephalitis
7%
West Nile Virus Infection
7%
Comorbidity
7%
Vaccination
7%
30-day Mortality
7%
Men Who Have Sex with Men
6%
Retrospective Cohort Study
6%
Older Adults
6%
Highly Active Antiretroviral Therapy (HAART)
6%
Surveillance Studies
6%
Bloodstream Infection
6%
PCV7
6%
Travellers
6%
Drug Resistance
6%
Antimicrobial Use
6%
Staphylococcus Aureus Bacteremia
6%
Independent Risk Factors
6%
Antibiotic Treatment
6%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
28%
Bloodstream Infection
27%
Infection
24%
Cohort Study
23%
Diseases
18%
Antiinfective Agent
14%
Pneumococcal Infection
12%
Methicillin-Resistant Staphylococcus Aureus
9%
Quinolone Derivative
9%
Prevalence
9%
West Nile Fever
9%
Rituximab
9%
Randomized Controlled Trial
8%
Antibiotics
8%
Hematologic Malignancy
6%
Pneumococcus Vaccine
6%
Antimicrobial Resistance
6%
Penicillin
6%
Combination Therapy
6%
2009 H1N1 Influenza
6%
Pneumocystis Jiroveci
6%
Coronavirinae
6%
SARS Coronavirus
6%
Enterobacteriaceae
6%
Aztreonam
6%
Piperacillin Plus Tazobactam
5%
Quinolone
5%
Antibiotic Therapy
5%
Amoxicillin
5%
Clavulanic Acid
5%
Mortality Rate
5%
Gentamicin
5%
Adverse Event
5%
Extended Spectrum Beta Lactamase
5%
Medicine and Dentistry
Human Immunodeficiency Virus
38%
Bloodstream Infection
17%
Infection
16%
COVID-19
15%
Cohort Analysis
12%
West Nile Fever
12%
Drug Resistance
10%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Antibiotic Therapy
10%
Diseases
9%
Antiretroviral Therapy
9%
Surgical Infection
9%
Pneumococcal Infection
9%
Rituximab
9%
Mortality Rate
9%
Prevalence
8%
Odds Ratio
7%
Omicron Coronavirus Variant
7%
Virus
6%
West Nile Virus
6%
Encephalitis
6%
Pneumocystis Jirovecii
6%
Enterobacteriaceae
6%
Human Immunodeficiency Virus Infection
6%
Combination Therapy
6%
High Risk Behavior
6%
Extended Spectrum Beta Lactamase
5%
Serotype
5%
Nonnucleoside Reverse Transcriptase Inhibitor
5%
Hematologic Malignancy
5%
Virus Infection
5%
Carbapenem
5%
Retrospective Cohort Study
5%
